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Background Higher waist circumference and lower hip circumference are both
associated with increased cardiovascular disease (CVD) risk, despite
being directly correlated. The real effects of visceral obesity may
therefore be underestimated when hip circumference is not fully
taken into account. We hypothesized that adding waist and hip
circumference to traditional risk factors would significantly improve
CVD risk prediction.
Methods In a population-based survey among South Asian and African
Mauritians (n¼7978), 1241 deaths occurred during 15 years of
follow-up. In a model that included variables used in previous
CVD risk calculations (a Framingham-type model), the association
between waist circumference and mortality was examined before
and after adjustment for hip circumference. The percentage with
an increase in estimated 10-year cumulative mortality of 425%
and a decrease of 420% after waist and hip circumference were
added to the model was calculated.
Results Waist circumference was strongly related to mortality only after ad-
justment for hip circumference and vice versa. Adding waist and hip
circumference to a Framingham-type model increased estimated
10-year cumulative CVD mortality by425% for 23.7% of those who
died and 15.7% of those censored. Cumulative mortality decreased by
420% for 4.5% of those who died and 14.8% of those censored.
Conclusions The effect of central obesity on mortality risk is seriously under-
estimated without adjustment for hip circumference. Adding waist
and hip circumference to a Framingham-type model for CVD mor-
tality substantially increased predictive power. Both may be
important inclusions in CVD risk prediction models.
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Introduction
The epidemic levels of overweight and obesity
observed in most developed countries are now being
seen in developing countries due to urbanization and
westernization. Obesity is an acknowledged risk factor
both for all-cause and cardiovascular disease (CVD)
mortality
1–11 but is not included in most CVD risk
models because body mass index (BMI) and waist
circumference have not sufficiently improved the pre-
dictive properties of such equations.
12–17
Hip circumference, although directly correlated with
waist circumference (and BMI), has been shown to
be inversely associated with blood glucose, blood pres-
sure and lipids.
18 It is also associated with reduced
risk of CVDs,
19–22 all-cause
23,24 and cardiovascular
mortality,
19,25 particularly when adjusted for waist
circumference.
21,23,26
This difference between the adverse effects of ele-
vated waist circumference on the one hand and
the protective effects of hip circumference on the
other may be due to the observation that most
of the pathological influence of adiposity is due to
visceral, rather than superficial, fat.
27 Waist circum-
ference is increased by increasing superficial fat,
and failing to account for this may underestimate
the real effects of visceral obesity. The waist-to-hip
ratio attempts to do this, but assumes that this can
be achieved by a simple ratio. Furthermore, a specific
protective role of gluteofemoral body fat via the regu-
lation of fatty acid release and uptake and a beneficial
adipokine profile is also now being recognised.
28
By improving the assessment of adiposity, we may
be able to improve CVD risk prediction. We therefore
hypothesized that adding waist and hip circumference
to traditional risk factors would significantly improve
CVD risk prediction.
We report here on the relationship between central
obesity, hip circumference and mortality in a popula-
tion-based cohort of almost 10000 African and
ethnically South Asian individuals from Mauritius,
with measured height, weight, waist and hip circum-
ference at studies in 1987, 1992 and 1998 and an
average of 15 years of mortality follow-up.
Methods and procedures
Mauritius is an Indian Ocean island  800km from
Madagascar. The population is largely of South
Asian Indian (68%) and African (Creole) (27%)
origin. African Mauritians are of mixed East African
and Malagasy ancestry (Malagasy ancestry being both
Malay and East African), with some European and
Indian admixture. The South Asian population are
mostly of Bihari origin (North-West India).
A population-based survey was conducted in
Mauritius, with measurements taken in 1987, 1992
and 1998, details of which were published previ-
ously.
29–32 In 1987, 10 randomly selected clusters
and a purposely selected area of Chinatown in the
capital city, Port Louis, were surveyed. In 1992 and
1998, previous participants were re-surveyed, along
with any new eligible residents of the 10 clusters.
Three additional clusters were added in 1992 and
re-surveyed in 1998. All individuals aged 525 years
(1987 and 1992) or 520 years (1998) were tested.
A total of 8932 individuals (71% Asian Indian,
29% African ancestry), participated in the three sur-
veys [excluding Chinese individuals (n¼626) who
were removed from this analysis]. Sixty percent par-
ticipated in more than one survey and 28% in
all three surveys. Response for each survey was
485%.
30 Informed written consent was obtained
from all participants. The mortality follow-up protocol
was reviewed and approved by the local ethics
committee (Ministry of Health and Quality of life,
Mauritius). The 1987, 1992 and 1998 surveys were
additionally approved by the ethics committee of
the International Diabetes Institute (Melbourne,
Australia).
Mortality follow-up was conducted between 1 April
and 30 October 2007. Contact with participants (or
their next of kin, other household members or neigh-
bours when participants were not contactable) was
used to determine vital and migration status.
National death registries were also used to verify
vital status and cause of death. Identity was validated
using name, age, address, ethnicity, number of chil-
dren and occupation from previous surveys. Where
possible, death certificates or certified extracts of the
certificate were inspected and cause of death noted.
Individuals were followed from the date of the first
interview. Participants whose vital status was un-
known, but who contributed some follow-up time
were censored at the date of last contact (n¼333).
Participants not contributing any follow-up time (at-
tended one survey and then were lost) were excluded
from all mortality analyses (n¼409), as were those
with a history of prior CVD or lower limb amputation
(n¼545). Vital status was established for a total of
7978 participants.
Measurements at each survey were conducted ac-
cording to identical protocols, except where stated.
A 75-g oral glucose-tolerance test was performed on
all non-pregnant participants, except those taking in-
sulin or oral hypoglycaemic drugs. Biochemical
OBESITY, HIP CIRCUMFERENCE AND MORTALITY 485measurements, height, weight and blood pressure
were measured as previously described.
29,30,33 Hip
circumference was measured as the maximum
circumference at the level of the buttocks. Waist cir-
cumference was measured as the minimum circum-
ference, in the horizontal plane, between the
xiphisternum and umbilicus in 1987 and as the cir-
cumference at the mid-point between the iliac crest
and the lower margin of the ribs in 1992 and 1998.
34
Mean waist circumference measured at the mid-point
between the ribs and the iliac crest has been shown to
be higher (1.5cm in men, 2.7cm in women) than at
the narrowest waist.
35 Therefore, 1987 waist circum-
ference values were increased accordingly. Obesity
(as a dichotomous variable) was classified using rec-
ommended Asian waist circumference cut-points
(580cm in women and 590cm in men) for the
South Asian population.
36 Information about smoking
status, ethnicity, treatment for hypertension and pre-
vious CVD or amputation was collected by
interviewer-administered questionnaire. Treatment
for hypercholesterolaemia was not assessed in this
study.
Consideration of the use of the words ‘confounding’
and ‘effect-measure modification’ in this study
were based on the definitions of Rothman and
Greenland.
37 They describe a confounder as being a
variable that: (i) is a risk factor for the disease; (ii) is
associated with the exposure (waist circumference in
this study); and (iii) is not in the causal pathway
between the exposure and the disease. ‘Effect-
measure modification’ refers to variation in the mag-
nitude of a measure of exposure effect across levels of
another variable. The variable across which the effect
measure varies is called an effect modifier.
Statistical analyses
We used a proportional hazard model (Cox model),
with current age as the underlying time scale for ana-
lysis of all-cause and CVD mortality. Entry date was
the date of each participant’s first survey, exit date the
date of last contact, emigration or death. Explanatory
variables (unless otherwise stated) were based on
those used previously to investigate reclassification
of risk in the Framingham Heart Study and included
age, sex, total cholesterol, high-density lipoprotein
(HDL) cholesterol, systolic blood pressure, diabetes
mellitus, blood pressure treatment and smoking,
updated on up to two occasions during the study
period in addition to the baseline assessment.
38 For
the relationship between mortality and each of waist
and hip circumference, we used natural splines with
four parameters each, with knots chosen so that the
number of deaths was the same between knots.
Scatter plots of waist vs hip circumference were over-
laid with a contour plot of the estimated hazard ratio
for death (relative to a reference individual of waist
85cm and hip 95cm) to illustrate the joint effect of
waist and hip. The linearity of the effects was tested
by replacing the natural splines by a linear function,
and the interaction between waist and hip circumfer-
ence was tested by adding the product or the ratio of
the variables to the model. All tests were likelihood
ratio tests, using the 
2 approximation. We computed
the 10-year cumulative mortality using models with
and without waist and hip, and compared changes
for persons with and without an event. We computed
the fraction of the sample where cumulative mortality
was increased by425% and decreased by420% (these
values being equidistant on a relative scale: 1.25/1¼1/
0.8), separately for those with and without an event.
We also plotted the cumulative mortality rates in the
two models to provide a graphical impression of the
improvement. Finally, we plotted the observed and
the mean predicted estimated cumulative CVD mor-
tality (a calibration plot for improvement of the model
upon the addition of waist and hip circumference) in
deciles of estimated cumulative mortality, as well as a
smoothed version of this using a spline model in lo-
gistic regression. Analysis was conducted using R
2.11.1.
39 Separate analyses were conducted for men
and women, Africans and South Asians.
Results
Over a median follow-up period of 15.1 years (max-
imum of 20.5 years), 1241 deaths occurred (56% in
men, 68% in South Asians), with 703 (56.6%) of these
being attributable to CVD. Death certificates or certi-
fied extracts were obtained for 927/1241 deceased par-
ticipants. Where these were not available, the cause of
death was preferentially derived from adjudication of
hospital files (n¼192) or next of kin (n¼100). No
information on cause of death was available for 22
participants. World Health Organization International
Classification of Diseases codes were not available on
certificates, and rarely in hospital data. We therefore
classified cause of death into 11 groups: cardiac
(n¼442, 35.6%); cerebrovascular (n¼185, 14.9%);
cancer (n¼165, 13.3%); trauma (n¼53, 4.3%); dia-
betes (n¼22, 1.8%); respiratory disease (n¼86,
6.9%); hypertension (n¼6, 0.5%); renal failure
(n¼70, 5.6%); gastrointestinal/hepatic/alcohol
(n¼78, 6.3%); other (n¼68, 5.5%); and not known
(n¼37, 3.0%). CVD mortality included deaths categor-
ized as cardiac, cerebrovascular, hypertension and
renal failure. Cause of death from death extract or
death certificate was adjudicated by a cardiologist
(S.S.) for  19% of deaths using hospital records.
Percentage agreement was 63%.
Those who died from CVD or other causes were
older and had higher levels of waist circumference
and waist-to-hip ratio than survivors at study entry
(Table 1). Hip circumference was positively correlated
with waist circumference (r¼0.76). Diabetes
486 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYprevalence was 13.0% in 1987, 17.8% in 1992 and
23.3% in 1998 in this cohort.
Before adjustment for hip circumference, no associ-
ation was seen between waist circumference and
CVD (P¼0.28) or all-cause mortality (P¼0.85) in a
model also containing those variables used in risk pre-
diction models based on the Framingham Heart Study
(age, sex, total cholesterol, HDL cholesterol, systolic
blood pressure, diabetes mellitus, blood pressure treat-
ment and cigarette smoking). After additional adjust-
ment for hip circumference, a strong and graded
relationship with both all-cause and CVD mortality
was seen for waist circumference (Figure 1,w i t hs e x -
and ethnicity-specific results presented in Figures 2
and 3 and Supplementary Figures S1–S6 available as
Supplementary Data at IJE online). Similarly, a strong
negative relationship between hip circumference and
both CVD and all-cause mortality was only observed
once adjusted for waist circumference (Figure 1). The
risk of death from both CVD and all causes was influ-
enced by both waist circumference and hip circumfer-
ence. The hazard ratio for CVD death in a fully
adjusted model was 1.31 per standard deviation (SD)
of waist circumference and 0.72 per SD of hip circum-
ference (both P<0.0001). Findings were unchanged
when those with diabetes were excluded, and in sub-
group analysis of those with either diabetes, impaired
fasting glucose or impaired glucose tolerance or those
with none of these conditions (results not shown). For
men only, we found a non-linear relationship between
waist circumference and all-cause and CVD mortality
(in both ethnic groups, P<0.05). A J-shaped
relationship was apparent with increasing risk of
death for greater waist circumference only 475cm.
We tested whether the relationship of each of waist
and hip circumference with mortality could be equally
well described by linear effects, which was not the
case (P-value for the addition of non-linear terms to
a model with linear terms <0.0001 for all-cause and
P¼0.026 for CVD mortality). In addition, we tested
whether either waist or hip could be omitted from the
model, which was strongly rejected (P-value for the
addition of the second term <0.002 for both variables
and both outcomes). Neither the inclusion of
waist-to-hip ratio (P¼0.242 for all-cause; P¼0.171
for CVD) nor the product of waist and hip circum-
ference [P¼0.08 (all-cause) and P¼0.083 (CVD)] im-
proved the model with non-linear terms of waist and
hip circumference. We tested whether waist-to-hip
ratio could replace the non-linear waist and hip cir-
cumference terms and this was also strongly rejected
(for the addition of waist and hip terms to a model
containing waist-to-hip ratio, P<0.0001 for all-cause;
P¼0.010 for CVD). Finally, the effect on the relation-
ship of waist circumference and CVD mortality upon
the addition to the model of height rather than hip
circumference was estimated, with waist circumfer-
ence remaining non-significant following the addition
of height (P¼0.26).
To assess change in predictive power of a
Framingham-type model upon the addition of waist
and hip circumference, estimated 10-year cumulative
CVD mortality was calculated for the base model, and
for an extended model including non-linear terms
Table 1 Characteristics of the cohort according to vital status and cause of death
a
CVD deaths Non-CVD deaths Survivors
N 703 538 6737
Age 57 (47.9–63.9) 54.6 (42.7–63.1) 36.8 (30.1–46.9)
Women (%) 43.4 (39.7–47.1) 43.7 (39.5–47.9) 56.6 (55.4–57.8)
Indian (%) 71.1 (67.8–74.5) 63.4 (59.3–67.5) 71.5 (70.4–72.5)
Creole (%) 28.9 (25.5–32.2) 36.6 (32.5–40.7) 28.5 (27.5–29.6)
Smokers (%) 39.4 (35.8–43) 42.5 (38.3–46.7) 25.6 (24.6–26.7)
Education (secondary or higher) (%) 12.1 (9.7–14.5) 15.1 (12.1–18.2) 39.2 (38–40.3)
Waist circumference 84 (75–90.5) 81 (72.7–89.5) 79.5 (71.8–87)
Hip circumference 92 (85–98) 89 (83–97) 92.5 (87–98.5)
Waist-to-hip ratio 0.9 (0.84–0.94) 0.88 (0.84–0.93) 0.85 (0.79–0.9)
BMI (kg/m
2) 24 (21–27.4) 23 (19.7–26.9) 23.7 (20.8–26.7)
Fasting plasma glucose (mmol/l) 5.9 (5.2–8.0) 5.6 (5.1–6.4) 5.2 (4.9–5.7)
2 hour plasma glucose (mmol/l) 7.5 (6.0–10.8) 7.0 (5.6–9.2) 6.3 (5.3–7.5)
HDL cholesterol (mmol/l) 1.2 (1.0–1.5) 1.3 (1.1–1.5) 1.2 (1.0–1.4)
Total cholesterol (mmol/l) 5.5 (4.6–6.4) 5.3 (4.5–6.2) 4.9 (4.2–5.8)
Systolic blood pressure (mmHg) 135 (121–155) 129 (117–143) 119 (109–130)
Diastolic blood pressure (mmHg) 82 (73–91) 79 (71–86) 73 (66–82)
aData are medians (inter-quartile range) or percentage (95% confidence interval).
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against each other separately for those with and with-
out an event (Supplementary Figure S7 available as
Supplementary Data at IJE online) with the figure
also including the quartiles, 10th and 90th centiles
of the distributions. This figure shows that adding
waist and hip circumference decreased the estimated
cumulative CVD mortality in those without events,
and increased it for those who died, thereby increas-
ing predictive power. A calibration plot of observed
and predicted 10-year cumulative CVD mortality risk
for these two models (Supplementary Figure S8 avail-
able as Supplementary Data at IJE online) shows im-
provement in model fit upon the addition of waist
and hip circumference.
Of those who died from cardiovascular causes, 23.7%
had an increase in estimated risk425% upon the add-
ition of waist and hip circumference to the model,
whereas 4.5% had a decrease in estimated risk of
420% (Table 2). Estimated mortality risk increased
for two-thirds of those who died from CVD upon add-
ition of waist and hip to the model. For those who
were censored (i.e. remained alive or died of a
non-CVD cause), the percentage whose estimated
risk increased by425% and the percentage whose esti-
mated risk decreased by 420% was similar, at  15%.
A similar pattern was observed for all-cause mortality.
Using the same Framingham-type model in the
South Asian population only, those above the recom-
mended Asian waist circumference cut-points for
obesity (80cm in women, 90cm in men) had a
hip-adjusted risk of CVD death 1.8 [95% confidence
interval (CI) 1.2–2.7] times greater in women and 1.5
(95% CI 1.1–2.2) times greater in men, compared with
those below the obesity cut-point. Before the inclu-
sion of hip circumference, central obesity according
to the relevant cut-points was not associated with
CVD mortality [women: 1.3 (95% CI 1.0–1.8),
P¼0.078; men: 1.0 (95% CI 0.8–1.3), P¼0.947].
In the Creole population, a similar effect of the
Asian obesity cut-point was seen, although the in-
crease in the relative risk upon the inclusion of hip
circumference in the model was less marked among
women (see Supplementary Table S1 available as
Supplementary Data at IJE online).
In a model not containing potential mediator vari-
ables (i.e. only adjusting for age, sex and smoking
status), waist circumference was significantly asso-
ciated with CVD mortality before adjustment for hip
circumference (hazard ratio per SD 1.16, P<0.0001);
however, this relationship was strengthened with the
addition of hip circumference to the model (hazard
ratio per SD 1.52, P<0.0001; P-value for the addition
of hip circumference <0.0001). In a model containing
AB
Figure 1 (A) Hazard ratio and 95% confidence interval for all-cause and CVD mortality according to waist and hip
circumference with (solid lines) and without (broken lines) adjustment for each other. (B) Contours of rate ratios for the
joint effect of waist and hip circumference on all-cause and CVD death (relative to a reference individual of waist 85cm and
hip 95cm). Waist circumference is plotted against hip circumference for persons with events (grey) and persons without
events (black)
488 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYonly age, sex and BMI, BMI was not associated with
CVD mortality in this cohort (P¼0.82). The addition
of hip circumference to the model did not change this
association (P¼0.62).
Discussion
Our results demonstrate the strong confounding
effect of hip circumference on the relationship
between obesity and both cardiovascular and all-
cause mortality. In this study of South Asian and
African Mauritians, the positive relationship of
waist circumference with CVD death in a fully
adjusted model only became apparent upon adjust-
ment for hip circumference (and vice versa).
Hip-adjusted waist circumference was a strong
predictor of CVD and all-cause mortality in both
men and women, South Asians and Africans. When
waist and hip circumference were both added to
a risk model for CVD death, which contained
those variables used in risk calculators based on the
Framingham Heart Study, predictive capacity
increased substantially.
Narrow hip circumference has been shown to be a
strong risk factor for mortality in several previous
studies among Europid populations,
19,23–26 although
in one study this finding was among men only.
19
A small number of studies have noted that, as we
found here, the strength of the relationship between
hip circumference and either heart disease or mortal-
ity only becomes apparent following adjustment for
waist circumference.
20,21,23 Almost no attention has
been given, however, to the impact of adjusting
waist circumference for hip circumference. Only
two studies that we are aware of have replicated
our finding that the effect of waist circumference
was underestimated (or absent) before adjustment
for hip circumference. Canoy et al.,
21 in their report
on the effects of body fat on risk of coronary heart
disease in the European Prospective Investigation of
Cancer-Norfolk study, noted that ‘adjustment for hip
circumference increased the risk prediction afforded
by using waist circumference alone by &10% to
&18% in men and women’.
21 Likewise, in the
large and multi-ethnic Epidemiological arm of the
Diabetes Reduction Assessment with Ramipril
and Rosiglitazone Medication (DREAM) trial
(EpiDREAM) cohort, De Koning et al.
40 observed
that the true effect of waist circumference on glucose
levels only became apparent after adjustment for both
waist and hip circumferences. We are not aware of
any studies that have previously reported the effect
on mortality risk of waist circumference adjusted for
hip circumference.
AB
Figure 2 (A) Hazard ratio and 95% confidence interval for all-cause and CVD mortality in Mauritian men accoding to waist
and hip circumference with (solid lines) and without (broken lines) adjustment for each other. (B) Contours of rate ratios
for the joint effect of waist and hip circumference on all-cause and CVD death in Mauritian men (relative to a reference
individual of waist 85cm and hip 95cm). Waist circumference is plotted against hip circumference for persons with events
(grey) and persons without events (black)
OBESITY, HIP CIRCUMFERENCE AND MORTALITY 489Several mechanisms may explain our findings. The
first is hinted at by the positive correlation between
hip and waist circumference, despite increases in
one measure being protective and increases in the
other detrimental. Specifically, waist circumference
effectively measures both visceral and subcutaneous
adipose tissue, whereas hip circumference provides
a more specific measure of subcutaneous gluteofe-
moral adipose tissue. Adjusting a measure of visceral
and subcutaneous adiposity for a measure of
subcutaneous adiposity may therefore provide a
more precise measure of visceral adipose tissue than
is possible by measurement of waist circumference
alone. Physiological explanations for our findings
may also be important, and include previously
observed differences in the effect of gluteofemoral
subcutaneous adipose and visceral subcutaneous adi-
pose tissue on metabolic health,
28,41,42 and the possi-
bility that larger hip circumference reflects greater
muscle mass. Manolopolous et al.
28 noted in their
AB
Figure 3 (A) Hazard ratio and 95% confidence interval for all-cause and CVD mortality in Mauritian women according to
waist and hip circumference with (solid lines) and without (broken lines) adjustment for each other. (B) Contours of rate
ratios for the joint effect of waist and hip circumference on all-cause and CVD death in Mauritian women (relative to a
reference individual of waist 85cm and hip 95cm). Waist circumference is plotted against hip circumference for persons
with events (grey) and persons without events (black)
Table 2 Percentage of individuals whose estimated 10-year cumulative mortality risk increased (by 0–25% and by
425%) or decreased (by 0–20% and by 420%) following the addition of waist and hip circumference to a base
Framingham-type model for all-cause and CVD death, stratified by whether they actually died or were censored
during the study period
Change in risk
All-cause mortality CVD mortality
Censored Dead Censored Dead
420% reduction 17.2 7.0 14.8 4.5
0–20% reduction 41.9 35.3 36.3 31.7
0–25% increase 24.0 29.1 33.2 40.1
425% increase 16.9 28.6 15.7 23.7
Total 100.0 100.0 100.0 100.0
490 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYreview on the topic that based on emerging evidence
from in vitro and in vivo studies of adipose tissue
physiology, ‘gluteofemoral fat may protect our
bodies, irrespective of gender, by trapping excess
fatty acids and preventing chronic exposure to ele-
vated lipid levels’. In addition, a beneficial adipokine
profile (leptin and adiponectin in particular) was also
suggested as a potential protective mechanism.
Whether the effects of lower body adipose tissue
differ between Europid and non-Europid populations
is largely unknown. On the one hand, Chowdhury
et al.,
43 in their study of Indian and Swedish men of
the same age and BMI, found higher glucose levels in
the South Asian men were due to differences in lower
leg muscle mass rather than differences in visceral fat,
potentially suggesting that physiological differences
between ethnic groups may lead to different effects
of hip circumference on mortality risk. On the other
hand, a powerful confounding effect of hip circumfer-
ence on the relationship of waist circumference with
glucose was observed in the multi-ethnic EpiDREAM
study [including Europid (53%), African (6.5%),
Latin American (8.1%), South Asian (20.3%) and
indigenous (12.1%) participants], which is suggestive
of a similar effect in populations other than the South
Asian and African populations included here.
40
Further studies including both waist and hip circum-
ference in different population groups and with dif-
ferent outcomes are clearly required.
26
Our finding of a marked increase in the predictive
capacity of a Framingham Heart Study-based model
for CVD or all-cause mortality following the addition
of waist and hip circumference suggests that these
anthropometric measures may be a useful addition
to such models in these populations. Taking account
of both waist and hip separately, rather than as a
ratio measure, has been shown in this study to be a
more powerful risk marker of premature death.
This supports the previous conclusion of Seidell
et al.
42 that the waist-to-hip ratio is a poor reflection
of the specific effects of each measurement,
23 as in-
dividuals with an identical waist-to-hip ratio can have
different waist and hip circumferences,
44 and using
a ratio measure prohibits examination of non-linear
associations between the numerator (waist) and the
denominator (hip).
20
The relationship between obesity and premature
mortality has not been widely studied in South
Asian populations. A large study from India, and
two studies from Bangladesh, found leanness, rather
than being overweight or obese, to be a major mor-
tality risk factor.
45–47 Those studies, however, were
conducted in lean, rural populations and did not
account for the protective effect of hip circumference.
In rural populations from less developed countries
(a large percentage of the native South Asian popula-
tions), low BMI reflects under-nutrition, low socio-
economic status, poor hygiene and higher resultant
mortality.
45,48 Urbanization, ageing of populations
and increasingly Western lifestyles mean that over-
weight and obesity are becoming increasingly import-
ant causes of death and disease in the developing
world.
49 A very recent pooled analysis of obesity and
risk of death that included two of the cohorts men-
tioned above, as well as a cohort study from Mumbai
with 13001 deaths, also failed to show an association
between BMI and risk of death.
50 Again, this study
did not account for the protective effect of hip circum-
ference, with their finding mirroring our observation
of no association between abdominal obesity and pre-
mature mortality before hip circumference was taken
into account.
The strengths of our study include response to the
baseline surveys of 485%, mortality follow-up of
491%, cause of death data for 498% of the cohort,
and the updating of risk factor status on up to two
occasions during the study period. The use of phys-
ician adjudication of hospital files (15.7%) or next-of-
kin interviews (8.2%) for ascertainment of cause of
death in some cases is a potential limitation. Since
the relationship between central obesity and CVD
mortality was strong, however, any misclassification
of CVD death is unlikely to have altered our interpret-
ation. It should be noted that the variables included
in our study were based on Framingham risk predic-
tion equations for fatal and non-fatal CVD,
16 even
though only fatal CVD was reported in this study
(data on non-fatal CVD were not available).
Furthermore, our analysis of the change in estimated
risk upon the addition of waist and hip circumference
to the model was based on relative change from
baseline (e.g. the proportion of individuals whose
risk increased by 425%) rather than more commonly
used methods that are dependent upon the cut-points
chosen and the baseline risk of the population, such
as the Net Reclassification Index.
51 Since the
Mauritius cohort used here has a particular age and
risk factor profile, comparisons with other cohorts
from more developed countries using such a measure
are not likely to be meaningful. Table 2 clearly shows
that, in this study, predicted risk increases consider-
ably among those who died, and decreases consider-
ably among those who were censored (did not die)
once waist and hip circumference are added to the
model.
Conclusions
Central obesity was a strong risk factor for death in
this cohort of African and ethnically South Asian
Mauritians, but only after adjustment for hip circum-
ference. The effect of central obesity on mortality may
be under-estimated without adjustment for hip cir-
cumference, and with such adjustment appears to sig-
nificantly improve the prediction of CVD and all-cause
mortality. Hip and waist circumference should be con-
sidered jointly for inclusion in CVD risk prediction
OBESITY, HIP CIRCUMFERENCE AND MORTALITY 491models and in the assessment of obesity-related risk
of future death.
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KEY MESSAGES
  The effect of central obesity (waist circumference) on mortality risk may be seriously underestimated
without adjustment for hip circumference.
  Adding waist and hip circumference to a Framingham-type risk model for CVD mortality increased
predictive capacity substantially in this study.
  All previous studies of obesity and mortality in South Asian populations have reported no association.
However, after adjustment for hip circumference, we have shown that this association is, in fact,
extremely strong.
  Both waist and hip circumference may be important inclusions in CVD risk prediction models, and
should be considered in studies of obesity and mortality.
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